Neuropace, Inc.
NPCE
Positions held
Your positionsNPCE isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $425.28M | Enterprise value | $443.51M | Trailing P/E | — | Forward P/E | -56.97 |
| PEG | — | Price / book | 35.71 | Beta | 1.87 | Dividend yield | 0.00% |
| Revenue growth | 17.1% | Earnings growth | — | Gross margin | 77.4% | Operating margin | -22.5% |
| Profit margin | -17.9% | ROE | -103.3% | ROA | -7.5% | Debt / equity | 5.88 |
| Current ratio | 4.94 | Free cash flow | -$2.63M | Analyst recommendation | none | Mean target | $20.00 |
| 52w high | $19.60 | 52w low | $9.22 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $22.8M | $22.1M | $26.6M | $27.4M | $19.5M | — |
| Op margin | -22.5% | -25.2% | -6.6% | -9.5% | -42.0% | — |
| Net income | -$6.2M | -$6.7M | -$2.7M | -$3.5M | -$8.7M | — |
| Gross margin | 82.8% | 81.8% | 77.4% | 77.4% | 83.1% | — |
| Gross profit | $18.9M | $18.0M | $20.6M | $21.2M | $16.2M | — |
| Operating income | -$5.1M | -$5.6M | -$1.8M | -$2.6M | -$8.2M | — |
- Revenue +3% vs prior quarter ($23M vs $22M).
- Gross margin 82.8% (was 81.8% prior quarter).
- Operating margin expanded to -22.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $100.0M | $79.9M | $65.4M | $45.5M | — |
| Op margin | -16.3% | -27.1% | -41.5% | -89.6% | — |
| Net income | -$21.5M | -$27.1M | -$33.0M | -$47.1M | — |
| Gross margin | 77.2% | 73.9% | 73.6% | 71.4% | — |
| Gross profit | $77.2M | $59.1M | $48.1M | $32.5M | — |
| Operating income | -$16.3M | -$21.7M | -$27.2M | -$40.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-18 · KeyBanc Initiates NeuroPace at Overweight With $18 Price Target
2026-09-10 · Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?
2026-09-04 · Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
2026-09-01 · NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
2026-08-31 · NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
2026-08-19 · NeuroPace Inc (NPCE) (Q2 2026) Earnings Call Highlights: Strong RNS Growth and AI Launch Offset ...
2026-08-17 · NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
2026-08-17 · Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
2026-08-17 · NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
2026-08-12 · NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
2026-08-12 · NeuroPace, Inc. Q2 2026 Earnings Call Summary
2026-08-12 · NeuroPace Q2 Earnings Call Highlights
Price (daily)
Full chart · RSI · MACD · patterns